XLONGENF
Market cap7mUSD
Dec 24, Last price
1.80GBP
1D
2.86%
1Q
-17.05%
IPO
-85.60%
Name
Genflow Biosciences PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-2m
L+21.97%
CFO
-2m
L+20.94%
Profile
Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. The company was incorporated in 2021 and is headquartered in London, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2021‑03 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 1,799 | 1,390 | 753 | |
Unusual Expense (Income) | ||||
NOPBT | (1,799) | (1,390) | (753) | |
NOPBT Margin | ||||
Operating Taxes | (4) | 1 | 99 | |
Tax Rate | ||||
NOPAT | (1,799) | (1,390) | (753) | |
Net income | (1,629) 21.97% | (1,335) 105.12% | (988) | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 3,763 | 784 | ||
BB yield | ||||
| Debt | ||||
Debt current | ||||
Long-term debt | ||||
Deferred revenue | ||||
Other long-term liabilities | 84 | |||
Net debt | (684) | (2,356) | (224) | |
| Cash flow | ||||
Cash from operating activities | (1,655) | (1,369) | (747) | |
CAPEX | (2) | (2) | ||
Cash from investing activities | (2) | (2) | 199 | |
Cash from financing activities | 3,500 | 784 | ||
FCF | (2,085) | (1,400) | ||
| Balance | ||||
Cash | 684 | 2,356 | 224 | |
Long term investments | ||||
Excess cash | 684 | 2,356 | 224 | |
Stockholders' equity | (3,465) | (1,995) | (721) | |
Invested Capital | 4,446 | 4,361 | 776 | |
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 292,507 | 292,507 | 292,507 | |
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | (1,798) | (1,390) | (753) | |
EV/EBITDA | ||||
Interest | 382 | 99 | ||
Interest/NOPBT | ||||